SUMMARY
Vaccination-induced protection against influenza is greatly diminished and increasingly heterogeneous with age. We investigated longitudinally (up to five timepoints) a cohort of 234 elderly influenza vaccinees across two independent seasons including up to six modalities (multi-omics and immunological parameters). System-level analyses revealed responders exhibited time-dependent changes attributed to a productive vaccine response across all omics layers whereas non-responders did not follow such dynamics, suggestive of systemic dysregulation. Through multi-omics integration, we identified key metabolites and proteins and their likely role in immune response to vaccination. High pre-vaccination IL-15 concentrations negatively associated with antibody production, further supported by experimental validation in mice revealing an IL-15-driven NK-cell axis with a suppressing role on antibody production. Finally, we propose certain long-chain fatty acids as modulators of persistent inflammation in non-responders. Our findings highlight the potential for stratification of vaccinees and open avenues for possible pharmacological interventions to enhance vaccine responses.
HIGHLIGHTS
Pre-vaccination pro-inflammatory status impedes vaccine responsiveness in the elderly.
Multi-omics integration reveals key molecules involved in vaccine response.
High pre-vaccination concentrations of IL-15 suppresses vaccine response through NK cell activation.
Certain long-chain fatty acids may act as modulators against chronic inflammation and are potential targets to improve vaccine response.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by an ERC starting Grant (948207), a Radboud University Medical Centre Hypatia Grant (2018) and the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) under Germany's Excellence Strategy - EXC 2155 project number 390874280 to YL and iMed, the Helmholtz Associations Cross Programme Initiative on Personalized Medicine, to CAG and FP. C-JX was supported by a Helmholtz Initiative and Networking Fund (1800167). MGN was supported by an ERC Advanced Grant (833247) and a Spinoza Grant of the Netherlands Organization for Scientific Research. LG research was supported by grants HR22-00741 (la Caixa Foundation), and 2022.04903.PTDC (Fundacao para a Ciencia e Tecnologia Portugal). This project was also partly supported by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 955321
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Hannover Medical School gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw data and code will be made available upon publication. Datasets are fully available for reviewers.
